 This was an open-label, single-dose BIA 2-093 800 mg tablet, single-centre study in five groups of subjects with various degrees of renal function based on creatinine clearance stages of renal function according to the Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products Guidelines for the evaluation of pharmacokinetics in patients with impaired renal function. 